Emily Bodnar, an analyst from H.C. Wainwright, has initiated a new Buy rating on BriaCell Therapeutics (BCT).
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Emily Bodnar’s rating is based on the promising clinical data and favorable safety profile of BriaCell Therapeutics’ Bria-IMT regimen in treating metastatic breast cancer (mBC). The Phase 2 study results showed a median overall survival (OS) of 13.9 months for patients treated with the Phase 3 formulation, which is notably higher than the outcomes reported for similar patients in existing literature. This is particularly impressive given the heavily pretreated nature of the patient population.
Additionally, the Bria-IMT regimen demonstrated a competitive clinical benefit rate (CBR) of 55% and was well tolerated among patients, with most adverse events being mild to moderate. The treatment showed promising efficacy across various breast cancer subtypes, including ER+/PR+/HER2-, HER2+, and TNBC, with significant improvements in progression-free survival (PFS) and OS. These encouraging results, along with the ongoing Phase 3 trials, underpin Bodnar’s Buy rating for BriaCell Therapeutics.